1. Home
  2. KPTI vs IKNA Comparison

KPTI vs IKNA Comparison

Compare KPTI & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • IKNA
  • Stock Information
  • Founded
  • KPTI 2008
  • IKNA 2016
  • Country
  • KPTI United States
  • IKNA United States
  • Employees
  • KPTI N/A
  • IKNA N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • IKNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • KPTI Health Care
  • IKNA Health Care
  • Exchange
  • KPTI Nasdaq
  • IKNA Nasdaq
  • Market Cap
  • KPTI 81.1M
  • IKNA 81.6M
  • IPO Year
  • KPTI 2013
  • IKNA 2021
  • Fundamental
  • Price
  • KPTI $0.62
  • IKNA $1.49
  • Analyst Decision
  • KPTI Strong Buy
  • IKNA Buy
  • Analyst Count
  • KPTI 4
  • IKNA 2
  • Target Price
  • KPTI $5.00
  • IKNA $3.00
  • AVG Volume (30 Days)
  • KPTI 768.4K
  • IKNA 169.0K
  • Earning Date
  • KPTI 02-19-2025
  • IKNA 03-11-2025
  • Dividend Yield
  • KPTI N/A
  • IKNA N/A
  • EPS Growth
  • KPTI N/A
  • IKNA N/A
  • EPS
  • KPTI N/A
  • IKNA N/A
  • Revenue
  • KPTI $148,442,000.00
  • IKNA $659,000.00
  • Revenue This Year
  • KPTI $4.47
  • IKNA N/A
  • Revenue Next Year
  • KPTI $7.35
  • IKNA N/A
  • P/E Ratio
  • KPTI N/A
  • IKNA N/A
  • Revenue Growth
  • KPTI 1.77
  • IKNA N/A
  • 52 Week Low
  • KPTI $0.58
  • IKNA $1.22
  • 52 Week High
  • KPTI $1.70
  • IKNA $1.94
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 43.29
  • IKNA 48.35
  • Support Level
  • KPTI $0.58
  • IKNA $1.40
  • Resistance Level
  • KPTI $0.67
  • IKNA $1.60
  • Average True Range (ATR)
  • KPTI 0.05
  • IKNA 0.07
  • MACD
  • KPTI -0.00
  • IKNA 0.01
  • Stochastic Oscillator
  • KPTI 31.02
  • IKNA 47.62

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Share on Social Networks: